Extreme Movers: Perplexity's picks for 2026-10-12
Perplexity picked HUM, TMUS, T, CCI, ASTS for a 1-day horizon. Average directional return: +0.26%. Directions called correctly: 60%.
| Experiment | Extreme Movers |
|---|---|
| Model | Perplexity |
| Prompt version | extreme-movers-v11 |
| Asked | |
| Horizon | 1-day |
| Measured from | 2026-10-09 |
| Measured to | 2026-10-12 |
| Benchmark | SPY |
| Status | Settled |
| Average directional return | +0.26% |
| Directions called correctly | 60% |
| Benchmark return | -0.06% |
The picks
| Rank | Symbol | Direction | Price change | Return in the called direction | Confidence | vs benchmark | Called right |
|---|---|---|---|---|---|---|---|
| 1 | HUM | up | +0.38% | +0.38% | 62% | +0.44% | Yes |
| 2 | TMUS | up | +2.21% | +2.21% | 60% | +2.27% | Yes |
| 3 | T | up | +1.40% | +1.40% | 58% | +1.46% | Yes |
| 4 | CCI | down | +1.72% | -1.72% | 55% | -1.66% | No |
| 5 | ASTS | down | +0.97% | -0.97% | 50% | -0.91% | No |
The model's market view
The S&P 500, Dow, and Nasdaq all closed higher on 2026-10-09, but the session produced unusually large, news-driven dispersion in healthcare and telecommunications. Humana and Crown Castle rallied on company- or industry-specific catalysts, while T-Mobile, AT&T, and AST SpaceMobile sold off sharply. For the next session, I favor a partial reversal in the most oversold telecom names, continuation in Humana's fundamental re-rating, and a reversal lower in Crown Castle after its outsized one-day advance.
Why each pick
HUM
Humana was among the session's leading large-cap gainers, closing up 11.29% at $430.84 on 2026-10-09 after its largest Medicare Advantage contract improved above the bonus-payment threshold, a substantive revenue-relevant catalyst. I expect continuation because the improvement affects future Medicare Advantage bonus revenue rather than being a purely technical momentum move. Risks are profit-taking after the large advance and broader managed-care sector volatility. The reference price is the latest quote found, $436.03 on 2026-10-10; market capitalization was verified at $52.36 billion and average daily share volume at 1.63 million shares, implying ample liquidity.
TMUS
T-Mobile fell 13.27% on 2026-10-09, closing at $148.58, after SpaceX's announced acquisition of a nationwide 800 MHz spectrum portfolio raised fears of future Starlink-based wireless competition. The catalyst is substantive in its long-run competitive implications, but the immediate revenue impact is uncertain and the transaction remains subject to FCC approval; the extreme one-day de-rating creates scope for a rebound. I expect reversal, with direction up, as investors reassess the near-term earnings impact. Risks include continued sector contagion, additional negative headlines, and the possibility that the market treats the threat as structurally material. The reference price is $148.76 on 2026-10-10; market capitalization was verified at $159.39 billion and average daily share volume at 5.63 million shares.
T
AT&T declined 10.81% on 2026-10-09 to a $22.18 close, its worst session since 2000, on the same SpaceX spectrum-competition news that hit the wireless group. I expect a reversal higher because the sell-off appears driven by a prospective, FCC-approval-dependent competitive scenario rather than an immediate change to AT&T's current wireless or fiber cash flows. The stock's high dividend yield and valuation may also attract dip buyers. Risks are that investors continue to price a durable competitive threat, that the move was only the first stage of a re-rating, and that telecom-sector sentiment remains weak. The reference price is $22.24 on 2026-10-10; market capitalization was verified at $151.88 billion and average daily share volume at 46.37 million shares.
CCI
Crown Castle surged 15.73% on 2026-10-09, closing at $79.68, as investors viewed tower operators as relative beneficiaries of SpaceX's push into wireless spectrum and potential network buildout. The catalyst has a substantive industry logic, but the one-day move was exceptionally large and the direct near-term financial benefit to Crown Castle is not yet quantified. I expect reversal, with direction down, as momentum traders take profits and the market distinguishes between a long-duration infrastructure opportunity and immediate earnings accretion. Risks include continued enthusiasm for tower exposure and a broader risk-on session. The reference price is the $79.71 after-hours quote on 2026-10-09; market capitalization was verified at $33.89 billion and average daily share volume at 4.59 million shares.
ASTS
AST SpaceMobile fell 9.55% during the 2026-10-09 session, with the quoted decline observed at 2:35 PM Eastern; I could not verify a closing percentage from the available sources, so this previous_change_percent reflects the latest verified intraday figure rather than a confirmed regular-session close. The decline occurred alongside the telecom-sector sell-off after SpaceX's spectrum announcement, which may pressure sentiment toward satellite-to-cell competitors. I expect continuation lower because ASTS is a high-beta, pre-profitability name whose valuation is sensitive to competitive and execution narratives. Risks include a sharp rebound if investors view ASTS as a beneficiary of satellite-based connectivity or if the broader telecom selloff stabilizes. The reference price is $50.93 on 2026-10-10; market capitalization was verified at $19.84 billion and average daily share volume at 17.33 million shares.
Other models on the same run
| Model | Picks | Average directional return | Directions called correctly |
|---|---|---|---|
| Grok 4.5 | CCI, MRNA, HUM, TMUS, T | -1.30% | 40% |
| Muse Spark 1.1 | LITE, CIEN, HUM, T, FSLY | -1.63% | 60% |
| GPT-6 | TMUS, HUM, CCI, AMT, ASTS | +0.33% | 60% |
| Gemini 1.5 Pro | CCI, HUM, MRNA, TMUS, DDOG | -0.62% | 60% |
| DeepSeek | FSLY, NVAX, TMUS, HUM, ALHC | -3.63% | 40% |
| Claude Sonnet 5.5 | HUM, MRNA, TMUS, CCI, FSLY | +3.13% | 80% |
Written up on ForecastNest Insights: Extreme Movers: Perplexity's picks for 2026-10-12.
ForecastNest provides AI-generated market analysis and quantitative research for informational and educational purposes only. Nothing here constitutes financial, investment, legal, or tax advice.